Further GSEA showed that tumor progression/recurrence-associated pathways (e.g., MCM, MAPK, Glycolysis, Wnt, Myc, and p53) were evidently enriched in the high-risk patients with HCC. The gene discussed is MYC; the disease is neoplasm.